Monday broker round-up
16th Mar 2015 15:59
Bodycote: N+1 Singer downgrades to hold. Morrrison: Deutsche Bank lifts target to 210p from 190p and reiterates hold. Centrica: Deutsche Bank reiterates hold and 280p target price. Rio Tinto: HSBC downgrades to neutral. IGas Energy: Cannacord Genuity lowers target to 85p from 125p and reiterates
Read moreBroker tips: Astrazeneca, Vodafone, Housing stocks
16th Mar 2015 11:44
Results from Astrazenca's Pegasus study of its blood-thinning Brilinta treatment received a cool reaction from the market on Monday, though analysts at UBS maintained their positive outlook for the product. The bank, which kept a 'buy' rating and 5,500p target price for the stock, said it still sees
Read moreLondon midday: China stimulus hopes help markets rebound
16th Mar 2015 11:43
Bargain hunting and hopes for stimulus measures in China gave UK stocks a lift on Monday, as investors readied for a busy week for financial markets worldwide. The FTSE 100 was up 0.5% at 6,776.87 by midday. The Footsie had lost 2.5% over the past five sessions on the back of a strengthening US dol
Read moreUBS still sees upside at Astrazeneca despite mixed Brilinta study results
16th Mar 2015 09:32
Results from Astrazenca's Pegasus study of its blood-thinning Brilinta treatment received a cool reaction from the market on Monday, though analysts at UBS maintained their positive outlook for the product. The bank said it still sees upside to consensus forecasts for Brilinta's sales despite the mi
Read moreLondon open: Stocks rebound after sell-off as markets eye Fed meeting
16th Mar 2015 08:30
UK stocks gained on Monday as investors hunted for bargains following a sharp slide in the value of the FTSE 100 over the last week. Ahead of a busy week for financial markets worldwide, the Footsie was up 0.4% at 6,767.46 early on. The index had lost 2.5% over the past five sessions on the back of
Read moreLondon pre-open: Gains expected ahead of busy week
16th Mar 2015 07:53
UK stocks were expected to rise on Monday morning following a poor showing by the FTSE 100 last week. City sources predict the Footsie will open 28 points higher than Friday's close of 6,740.58. A strengthening US dollar, concerns about Greece and slowdown worries in China dampened stocks last week
Read moreBrilinta sales potential rises at Astrazeneca after positive Pegasus study
16th Mar 2015 07:07
Results from Astrazeneca's much-anticipated Pegasus study of its Brilinta treatment found that the drug could extend patients' lives following a heart attack, though it did carry risks of increased bleeding. Studying the effects of the blood-thinning drug on 21,000 patients, Astrazeneca found it red
Read moreThursday broker round-up
12th Mar 2015 17:30
Asos: Cannacord Genuity raises target to 3,250p from 2,520p and reiterates hold. Cambian Group: Cannacord Genuity lifts target to 311p from 294p and reiterates buy. BP: JP Morgan raises target to 410p from 400p and reiterates underweight. Royal Dutch Shell: Investec reiterates hold. Supergroup: C
Read moreLondon close: Gains pared but markets buoyed by pharma, beverage stocks
12th Mar 2015 16:42
UK stocks were off their highest levels of the day by the close on Thursday as mining shares erased earlier gains, though strong performances from pharma and beverage groups provided some support, as well as M&A in the banking sector. The FTSE 100 finished the session up 39.56 points (+0.6%) at 6,76
Read moreFTSE 100 movers: Astrazeneca soars on new diabetes research, RBS higher on upgrade
12th Mar 2015 14:00
AstraZeneca topped the risers as it committed $40m to backing phase 2a trials for a new diabetes drug - a form of long-acting insulin that only needs to be administered once week. Glaxosmithkline was boosted by news it plans to sell approximately half of its 12.4% stake in Aspen Pharmacare Holdings.
Read moreLondon pre-open: Positive start expected after record close on Wall Street
3rd Mar 2015 07:50
UK stocks are expected to open with modest gains on Tuesday following a decent performance on Wall Street the night before, as investors watch corporate earnings on a quiet day for economic data. City sources predict the FTSE 100 will open 10 points higher than Monday's close of 6,940.64. Both the
Read moreAstraZeneca completes acquisition of rights to Activis
3rd Mar 2015 07:10
AstraZeneca has completed its acquisition of the rights to Activis' branded respiratory business in the US and Canada. The company paid Activis initial consideration worth $600m as well as an extra $100m for a number of contractual consents and approvals. According to an investor note released on T
Read moreFTSE 100 movers: Astrazeneca lower as patent rejected, BHP boosted by Pakistan disposal
16th Feb 2015 14:11
Astrazeneca was trading lower after its patent on its Pulmicort Respules treatment for asthma was ruled by a US court as invalid. The US District Court of New Jersey ruling paves the way for generic versions of the lung drug to be released into the market. Actavis said it released a version of the d
Read moreUS court invalidates Astrazeneca's asthma drug
16th Feb 2015 10:11
Astrazeneca's patent on its Pulmicort Respules treatment for asthma has been ruled by a US court as invalid. The US District Court of New Jersey ruling paves the way for generic versions of the lung drug to be released into the market. Actavis said it released a version of the drug following the cou
Read moreFTSE 100 movers: BT higher on EE takeover Easyjet nosedives on weak passenger numbers
5th Feb 2015 14:55
BT surged after confirming reports it has settled on terms of its acquisition of EE from Deutsche Telekom and Orange, saying it will be spending £12.5bn on the UK mobile network. The deal will be financed by new debt and a £1bn placing of its shares and will result in Deutsche Telekom and Orange tak
Read more